Drug Approval Package
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drug Approval Package

  • Print
  • Share
  • E-mail

COMPLERATM (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) 200 mg/25 mg /300 mg fixed dose combination tablets
Company: Gilead Sciences, Inc.
Application No.: 202123
Approval Date: 08/10/2011

Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance.


Date created: September 6, 2012

Back to Top    Drugs@FDA

Vision impaired people having problems accessing certain pages of a PDF file may call (301) 796-3634 for assistance.

Note: Documents in PDF format require the Adobe Acrobat Reader®.